Subcutaneous immunotherapy for the treatment of allergies: a review of the clinical efficacy, safety and guidelines

Record ID 32012000698
Authors' recommendations: Some marginal beneficial effect of subcutaneous immunotherapy (SCIT) was found in the treatment of patients with asthma or rhinitis compared with placebo; however, no evidence on SCIT in comparison with placebo, antihistamine or SLIT was from Canada. Existing guidelines recommended that SCIT can only be used as a "third line treatment" after avoidance allergen and conventional pharmacotherapy, and the adverse events including anaphylaxis must be fully discussed with patients; however, no Canadian guidelines on SCIT was identified.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Injections, Subcutaneous
  • Hypersensitivity
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.